DK1711513T3 - Nanofiltrering af faktor VII opløsninger for at fjerne virus - Google Patents

Nanofiltrering af faktor VII opløsninger for at fjerne virus

Info

Publication number
DK1711513T3
DK1711513T3 DK04804635.3T DK04804635T DK1711513T3 DK 1711513 T3 DK1711513 T3 DK 1711513T3 DK 04804635 T DK04804635 T DK 04804635T DK 1711513 T3 DK1711513 T3 DK 1711513T3
Authority
DK
Denmark
Prior art keywords
nanofiltration
factor vii
remove virus
solutions
vii solutions
Prior art date
Application number
DK04804635.3T
Other languages
Danish (da)
English (en)
Inventor
Jesper Christensen
Erik Halkjaer
Turid Preuss
Thomas Budde Hansen
Nina Johansen
Lene Vaedele Madsen Tomoda
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1711513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of DK1711513T3 publication Critical patent/DK1711513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04804635.3T 2003-12-01 2004-12-01 Nanofiltrering af faktor VII opløsninger for at fjerne virus DK1711513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301775 2003-12-01
PCT/EP2004/053206 WO2005054275A2 (en) 2003-12-01 2004-12-01 Nanofiltration of factor vii solutions to remove virus

Publications (1)

Publication Number Publication Date
DK1711513T3 true DK1711513T3 (da) 2014-09-15

Family

ID=34639198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04804635.3T DK1711513T3 (da) 2003-12-01 2004-12-01 Nanofiltrering af faktor VII opløsninger for at fjerne virus

Country Status (14)

Country Link
US (8) US20070142625A1 (enExample)
EP (3) EP1711513B1 (enExample)
JP (3) JP4874806B2 (enExample)
KR (1) KR101234170B1 (enExample)
CN (3) CN102351953B (enExample)
AU (1) AU2004294403A1 (enExample)
BR (1) BRPI0416950B8 (enExample)
CA (1) CA2545474A1 (enExample)
DK (1) DK1711513T3 (enExample)
ES (2) ES2507091T3 (enExample)
PL (1) PL1711513T3 (enExample)
PT (1) PT1711513E (enExample)
RU (1) RU2472804C2 (enExample)
WO (1) WO2005054275A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
PL2697369T3 (pl) 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
WO2013192009A1 (en) 2012-06-21 2013-12-27 Baxter International Inc. Virus filtration of cell culture media
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
CN115177759B (zh) * 2013-11-15 2024-07-23 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP1479395A1 (en) 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) * 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
EP1029546A1 (en) 1997-11-05 2000-08-23 Yoshitomi Pharmaceutical Industries, Ltd. Heparin cofactor ii preparations and process for producing the same
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
EP2226385B1 (en) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
AU2001291653A1 (en) * 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
ES2432967T3 (es) 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
HUP0500060A3 (en) 2001-09-27 2010-01-28 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003092588A2 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
EP1528930B1 (de) 2002-07-23 2009-04-15 Bio & Bio Licensing SA Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
EP1523327A1 (de) 2002-07-23 2005-04-20 Bio-Products & Bio-Engineering Aktiengesellschaft Thrombingenerierfahige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
JP4472526B2 (ja) 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
AU2004294403A1 (en) * 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Also Published As

Publication number Publication date
EP3594222B1 (en) 2022-08-03
US20080274534A1 (en) 2008-11-06
CN102351953A (zh) 2012-02-15
JP5666359B2 (ja) 2015-02-12
US20070142625A1 (en) 2007-06-21
US20120115204A1 (en) 2012-05-10
BRPI0416950B8 (pt) 2021-05-25
EP1711513A2 (en) 2006-10-18
US9102762B2 (en) 2015-08-11
JP4874806B2 (ja) 2012-02-15
ES2507091T3 (es) 2014-10-14
CN106916802A (zh) 2017-07-04
JP2011173889A (ja) 2011-09-08
WO2005054275A2 (en) 2005-06-16
CA2545474A1 (en) 2005-06-16
BRPI0416950A (pt) 2007-02-13
EP1711513B1 (en) 2014-07-02
RU2472804C2 (ru) 2013-01-20
EP2275432A1 (en) 2011-01-19
US20150299685A1 (en) 2015-10-22
RU2006118024A (ru) 2008-01-10
EP3594222A1 (en) 2020-01-15
PT1711513E (pt) 2014-10-02
US20190032026A1 (en) 2019-01-31
US20220064605A1 (en) 2022-03-03
US20170022482A1 (en) 2017-01-26
KR20070001887A (ko) 2007-01-04
WO2005054275A3 (en) 2005-09-09
JP2012021007A (ja) 2012-02-02
US20200248150A1 (en) 2020-08-06
CN102351953B (zh) 2017-05-10
CN106916802B (zh) 2022-03-25
JP2007537994A (ja) 2007-12-27
BRPI0416950A8 (pt) 2019-01-22
KR101234170B1 (ko) 2013-02-18
AU2004294403A1 (en) 2005-06-16
CN1890257A (zh) 2007-01-03
PL1711513T3 (pl) 2014-12-31
BRPI0416950B1 (pt) 2019-05-28
ES2926359T3 (es) 2022-10-25

Similar Documents

Publication Publication Date Title
DK2044028T3 (da) Cyanoisoquinolinforbindelser til stabilisering af den hypoxiinducerende faktor (HIF)
DK1877568T4 (da) Hydrolysering af arabinoxylan
DK1976516T3 (da) Behandling af viral hepatitis
DK1912999T3 (da) Makrocykliske inhibitorer af hepatitis-c-virus
DK1912997T3 (da) Makrocycliske inhibitorer af hepatitis C virus
DK1919898T3 (da) Makrocykliske inhibitorer af hepatitis-C-virus
DK1653807T3 (da) Anvendelse af dermale mikroorganer
DK1912981T3 (da) Makrocykliske inhibitorer af Hepatitis C-virus
DK1912995T3 (da) Makrocykliske inhibitorer af hepatitis C virus
DK1919899T3 (da) Makrocykliske inhibitorer af hepatitis C virus
DK1913014T3 (da) Makrocykliske inhibitorer af hepatitis-c-virus
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
DK1647529T3 (da) Fremgangsmåde til oprensing af spildevand
DK1720802T3 (da) Okidation af organiske forbindelser ved højt pH
DK1781400T3 (da) Rensning af forbrændingsgas herunder fjernelse af co2
DK1786472T3 (da) Antisense-modulering af apolipoprotein B-ekspression
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
EP1814982A4 (en) IMPROVED METHOD FOR CLEANING VIRUSES
HN2009000157A (es) Profarmacos de compuesto de cinamida
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1992697T3 (da) Fremstilling af TNFR-Fc
DK2377869T3 (da) Syntese af Bortezomib
DK1831357T3 (da) Genvinding af influenzavirus
DK1858917T3 (da) Varicella-zoster-virus-vaccine